Bristol Myers Says Experimental Cancer Therapy Improved Progression-Free Survival
Bristol Myers Squibb said its experimental radiopharmaceutical therapy significantly improved progression-free survival in a late-stage study of patients with advanced rare gastrointestinal and pancreatic tumors whose disease had progressed after prior treatment.
Bristol Myers Squibb (NYSE:BMY) said Monday that its experimental radiopharmaceutical therapy significantly improved progression-free survival in a late-stage study involving patients with advanced, rare gastrointestinal and pancreatic tumors whose disease had progressed following earlier treatment.